In a preclinical model of papillary renal cell carcinomas harbouring NF2 loss25, inhibition of the YAP1 partner YES1 by dasatinib or saracatinib led to repression of Hippo transcriptional targets and provided potent antitumour activity. The gene discussed is YES1; the disease is papillary renal cell carcinoma.